AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25055554
Drug: Intravenous ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ozone therapy and small doses of direct current (20-25mkA)
Trial: 16186468
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with aspirin alone
Trial: 16186468
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus colchicine (1.0-2.0 mg the first day and then 0.5-1.0 mg/d for 6 months)
Trial: 1906935
Drug: Gold sodium
RxNorm normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold sodium thiomalate (GSTM) 50 mg intramuscularly for 6 months
Trial: 1906935
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 15 mg intramuscularly for 6 months
Trial: 6600579
Drug: Erythromycin ethylsuccinate
RxNorm normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin ethylsuccinate (40 mg/kg/day every six hours for seven days)
Trial: 30165750
Drug: Clemastine 2
RxNorm normalized name: clemastine 2 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine 2 mg (1 mg/ml)
Trial: 30165750
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline 2 ml)
Trial: 28296735
Drug: Remifentanil (infused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (infused at 0.1 μg/kg/min with demand boluses of 0.1 μg/kg)
Trial: 27012255
Drug: In-home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-home treatment (preferred modality in choice condition)
Trial: 24525810
Drug: Reboxetine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (4 mg twice daily)
Trial: 15365306
Drug: Injectable naltrexone
RxNorm normalized name: naltrexone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable naltrexone (400 mg, administered intramuscularly once every 28 days for 4 months)
Trial: 15365306
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (matching to naltrexone, administered once every 28 days for 4 months)
Trial: 11226444
Drug: Constant 17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant 17beta‐estradiol (E2), 1 mg, plus intermittent norgestimate (NGM) 90 microg (3 days off, 3 days on)
Trial: 11226444
Drug: E2 2
RxNorm normalized name: PGE2 20 MG Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 2 mg/norethisterone acetate (NETA) 1 mg
Trial: 7986315
Drug: Fluvastatin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 2.5 mg q.p.m.
Trial: 7986315
Drug: Fluvastatin 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 5 mg q.p.m.
Trial: 7986315
Drug: Fluvastatin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 10 mg q.p.m.
Trial: 7986315
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg q.p.m.
Trial: 30982442
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose astaxanthin (≥20 mg/day)
Trial: 30982442
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose astaxanthin (<20 mg/day)
Trial: 26003264
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (including dietary advice)
Trial: 23305646
Drug: GcgR agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GcgR agonist
Trial: 23305646
Drug: Natural glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Natural glucagon injection
Trial: 10390394
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP), 1,000 micrograms twice a day
Trial: 10390394
Drug: Budesonide (BUD),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (BUD), 800 micrograms twice a day
Trial: 10390394
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP), 200 micrograms twice a day
Trial: 10390394
Drug: Budesonide (BUD),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (BUD), 200 micrograms twice a day
Trial: 2067759
Drug: Magnesium pyrrolidone
RxNorm normalized name: Pyrrolidone
DrugBank: Pyrrolidone (DB19152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium pyrrolidone carboxylic acid (360 mg Mg) administered three times a day from the 15th day of the menstrual cycle to the onset of menstrual flow
Trial: 2067759
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered three times a day from the 15th day of the menstrual cycle to the onset of menstrual flow
Trial: 6336937
Drug: Intramuscular cephaloridine
RxNorm normalized name: cephaloridine
DrugBank: Cefaloridine (DB09008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular cephaloridine (three 1-g perioperative doses)
Trial: 6336937
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin base and neomycin sulfate (three 1-g preoperative doses)
Trial: 28051337
Drug: Trauma-Focused Cognitive-Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT) for 12 sessions (n=40)
Trial: 26695667
Drug: PCT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT group (antibiotic therapy guided by serum procalcitonin)
Trial: 26695667
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard therapy according to clinical guidance)
Trial: 12671541
Drug: Isoflavone supplement
RxNorm normalized name: Soyrel Soy Isoflavone Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone supplement (100 mg daily)
Trial: 11269917
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (2.5% lidocaine and 2.5% prilocaine in oil emulsion) applied 2 hours prior to microneurography
Trial: 11269917
Drug: Aqueous placebo
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous placebo cream applied 2 hours prior to microneurography
Trial: 8147088
Drug: Complex physical
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex physical therapy (CPT) including special lymphatic massage after surgical reconstruction
Trial: 8147088
Drug: Complex physical
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex physical therapy (CPT)
Trial: 3524119
Drug: Desenkephalin-gamma-endorphin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desenkephalin-gamma-endorphin (3 mg)
Trial: 23946347
Drug: 3.3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.3 g/d oat β-glucans for 3 weeks
Trial: 23946347
Drug: 3.3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.3 g/d oat β-glucans
Trial: 10942739
Drug: Lotrafiban 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotrafiban 5 mg
Trial: 10942739
Drug: Lotrafiban 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotrafiban 100 mg
Trial: 10942739
Drug: Lotrafiban (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotrafiban (all doses)
Trial: 8769625
Drug: Pentoxifylline administered
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline administered intravenously 90 min before penicillin injection
Trial: 3532771
Drug: Dialysate calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate calcium of 2.5 mEq/L
Trial: 3532771
Drug: Dialysate calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate calcium of 3.5 mEq/L
Trial: 29749113
Drug: Initial anti-viral
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial anti-viral therapy (valaciclovir 500-1000 mg 1-3 times daily, aciclovir 200-400 mg 1-5 times daily, topical aciclovir 2-5 times daily, topical trifluorothymidine two hourly or as needed)
Trial: 29749113
Drug: Evidence-based anti-viral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based anti-viral therapy
Trial: 29749113
Drug: Indication and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indication and dose of prescribed anti-virals
Trial: 26248652
Drug: Venlafaxine extended
RxNorm normalized name: Desvenlafaxine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine extended release (37.5 mg), twice daily, through last dose of oxaliplatin
Trial: 21208597
Drug: Zolpidem extended-release
RxNorm normalized name: zolpidem Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem extended-release 12.5 mg/night
Trial: 21208597
Drug: Zolpidem extended-release/escitalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem extended-release/escitalopram
Trial: 12269458
Drug: Toothpaste containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothpaste containing 440 ppmF (Colgate 0‐6 Gel)
Trial: 9494149
Drug: Misoprostol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (200 microg four times daily)
Trial: 9494149
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole (maintenance therapy)
Trial: 9494149
Drug: Misoprostol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (200 microg twice daily, maintenance therapy)
Trial: 9494149
Drug: Placebo (maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maintenance therapy)
Trial: 8033494
Drug: Torsemide 50
RxNorm normalized name: torsemide 50 MG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torsemide 50 mg
Trial: 8033494
Drug: Torsemide 100
RxNorm normalized name: torsemide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torsemide 100 mg
Trial: 8033494
Drug: Torsemide 200
RxNorm normalized name: torsemide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torsemide 200 mg
Trial: 12366873
Drug: S-adenosyl-L-methionine (SAMe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (SAMe) 800 mg in 250 ml isotonic solution
Trial: 12366873
Drug: Placebo 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 250 ml isotonic solution
Trial: 29796649
Drug: Two Letters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two Letters + Counseling Call (CC arm)
Trial: 29804416
Drug: Mild hypothermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild hypothermia therapy (maintained at 35±1 ℃ for 5-7 days)
Trial: 29804416
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (RT) including bloody cerebrospinal fluid drainage, spasmolysis, 3H treatment, etc.
Trial: 24832638
Drug: Paclitaxel drug‐eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel drug‐eluting balloons (pDEB) plus bare metal stent (BMS)
Trial: 22396515
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 50 mg/wk + placebo
Trial: 22396515
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 125 mg/wk + placebo
Trial: 22396515
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 300 mg/wk + placebo
Trial: 22396515
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 600 mg/wk + placebo
Trial: 22396515
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 50 mg/wk + dutasteride
Trial: 22396515
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 125 mg/wk + dutasteride
Trial: 22396515
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 300 mg/wk + dutasteride
Trial: 22396515
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 600 mg/wk + dutasteride
Trial: 16109551
Drug: ACEI (ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI (ramipril starting dose of 2.5 mg/d gradually reaching 5 mg/d)
Trial: 16109551
Drug: ARB (irbesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB (irbesartan with gradual increase of doses till reaching maximum daily dose of 150 mg)
Trial: 2775616
Drug: Halofantrine 250
RxNorm normalized name: halofantrine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine 250 mg fasting
Trial: 2775616
Drug: Halofantrine 250
RxNorm normalized name: halofantrine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine 250 mg after fatty meal
Trial: 2775616
Drug: Halofantrine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine 500 mg
Trial: 2775616
Drug: Halofantrine 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine 1000 mg
Trial: 2775616
Drug: Halofantrine 250
RxNorm normalized name: halofantrine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine 250 mg fasting vs 250 mg after fatty meal
Trial: 2775616
Drug: Halofantrine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine 500 mg vs 1000 mg
Trial: 29599530
Drug: anti-CD19 CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-CD19 CAR T-cell therapy
Trial: 30592549
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin tregopil (IN‐105)
Trial: 28415636
Drug: Leflunomide +
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leflunomide + low-dose corticosteroid
Trial: 28415636
Drug: Full-dose corticosteroid
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose corticosteroid
Trial: 25608756
Drug: Prednisone 50
RxNorm normalized name: prednisone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 50 mg daily for 7 days
Trial: 22696891
Drug: Methylphenidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.3 mg/kg/d + zinc sulfate 10 mg/d (GZN)
Trial: 22696891
Drug: Methylphenidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.3 mg/kg/d + placebo (GPL)
Trial: 19696423
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg once daily for 10 days)
Trial: 19696423
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) (5000 U every 12 hours for 10 days)
Trial: 11371662
Drug: Trocade 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trocade 25 mg
Trial: 11371662
Drug: Trocade 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trocade 50 mg
Trial: 11371662
Drug: Trocade 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trocade 100 mg
Trial: 11371662
Drug: Trocade 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trocade 150 mg
Trial: 3297678
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg kg‐1 captopril pre‐treated patients
Trial: 29804892
Drug: Horticultural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horticultural therapy (HT), 60-minute sessions for 8 weeks
Trial: 27155586
Drug: Rivaroxaban mono-therapy
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban mono-therapy
Trial: 27155586
Drug: Standard-therapy with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-therapy with enoxaparin followed by vitamin K antagonist (VKA)
Trial: 25530057
Drug: Injection at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection at a seeking current of 0.8 mA
Trial: 25530057
Drug: Injection at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection at a seeking current of <0.5 mA
Trial: 24473591
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine - ma zi ren wan (MZRW) 7.5 g bid
Trial: 14522478
Drug: Clopidogrel pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel pretreatment (300 mg before PCI)
Trial: 22805313
Drug: Low-dose Korean
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Korean red ginseng (3 g/day)
Trial: 22805313
Drug: High-dose Korean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Korean red ginseng (6 g/day)
Trial: 22805313
Drug: KRG supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRG supplementation (both doses)
Trial: 19194969
Drug: Trans-resveratrol 25
RxNorm normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trans-resveratrol 25 mg, six times/day for thirteen doses
Trial: 19194969
Drug: Trans-resveratrol 50
RxNorm normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trans-resveratrol 50 mg, six times/day for thirteen doses
Trial: 19194969
Drug: Trans-resveratrol 100
RxNorm normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trans-resveratrol 100 mg, six times/day for thirteen doses
Trial: 19194969
Drug: Trans-resveratrol 150
RxNorm normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trans-resveratrol 150 mg, six times/day for thirteen doses
Trial: 9951927
Drug: Adjuvant locoregional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant locoregional chemoimmunotherapy (Gemcitabine 1 gm/m2, Carboplatin 200 mg/m2, Mitoxantrone 0.2 g/kg bw, IL-2, gamma-IFN)
Trial: 7924365
Drug: Medications containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications containing glucose
Trial: 31582622
Drug: LDL-C lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C lowering drug therapy (primarily statins)
Trial: 31582622
Drug: No LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No LDL-C lowering drug therapy
Trial: 14648073
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1000 mg calcium carbonate for 6 weeks)
Trial: 7871090
Drug: alpha-2 adrenoceptor
RxNorm normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-2 adrenoceptor antagonist (high dose)
Trial: 28978818
Drug: G1-DES (First-Generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G1-DES (First-Generation Drug-Eluting Stents)
Trial: 28978818
Drug: G2-DES (Second-Generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G2-DES (Second-Generation Drug-Eluting Stents)
Trial: 19320897
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure instillation therapy
Trial: 19320897
Drug: Standard surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surgical debridement with gentamicin polymethylmethacrylate beads and long‐term intravenous antibiotics (Control)
Trial: 10813543
Drug: Mobilization with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobilization with cyclophosphamide (CY) plus G-CSF
Trial: 10813543
Drug: Mobilization with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobilization with CY plus GM-CSF (8 days) followed by G-CSF
Trial: 8925804
Drug: High-protein meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein meal (80 gm total protein: 4.1 g phenylalanine, 8.2 g leucine, 4.2 g isoleucine, 52 g carbohydrate, 9 g fat)